LB23

N/A

Report date: 2023/03/02 16:29:20
NME

Base Information

Drug NameLB23
Drug Alias NameLB23
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionPoly (ADP-Ribose) polymerase 1 degraders
TargetsPoly (ADP-Ribose) polymerase 1
Therapy Area/IndicationsTriple Negative Breast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesWest China Hospital Of Sichuan University
China Registration ClassN/A

Develop Information

Active CompaniesWest China Hospital Of Sichuan University
Inactive CompaniesN/A
Active IndicationsTriple Negative Breast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A